Houston claimed the No. 1 spot among the 50 most visited in the U.S. with the lowest carbon footprint. Sean Pavone/Getty Images

People looking to travel to a sustainable city probably don’t have Texas spots at the top of their lists. Images of oil, cars, and blasting air conditioners spring up. The Texas power grid, no one need remind us, is barely hanging on.

But Texas blew other states away for lowest carbon footprint per capita, landing Houston at the top of the list compiled by travel blog Park Sleep Fly. Austin followed (No. 3), then San Antonio (No. 4) and Dallas (No. 9). Only Florida appeared twice in the top 10, and none matched Texas with four cities.

Among the 50 most visited in the U.S., those with the lowest carbon footprint are:

1. Houston
2. Los Angeles
3. Austin
4. San Antonio
5. Tampa, Florida
6. Salt Lake City
7. Phoenix
8. Miami
9. Dallas
10. Portland, Oregon

Houston is not exactly a green place, with less-than-ideal utilization of public transportation. It and Dallas tied for third place among least sustainable cities in the same report.

“Public transit isn’t the most popular mode of transportation in Houston, but it does exist,” an online publication called TripSavvy drably admits. The city takes credit for employing “nearly one third” of the nation’s oil and gas extraction workers.

On the renewable side, however, Houston claims more than 100 solar energy companies, and at least half of its corporate research and development centers pursue “energy technology and innovation.” And its huge population spreads the load, leaving only 14.6 metric tons of carbon dioxide per resident — the same as Los Angeles. Big cities seem to have an advantage in this rating system.

Austin is just behind Houston at 15 metric tons per capita, neck-and-neck with San Antonio at 15.2. These two cities have smaller populations to distribute their total footprint, but are generally seen as eco-friendly. Austin got a big head start in 1991 with the introduction of the Austin Energy Green Building program — the first of its kind in the whole country — which created an evaluation system for individual building sustainability that’s still in use. Dallas' carbon footprint is the largest of the Texas cities in the ranking, at 16.5 metric tons per capita.

As such a multifaceted issue (especially tied up in economic concerns), sustainability is hard to pin down from city to city. The multiplicity of this list is yet another indicator that Texas as a whole is a much more nuanced place than many people think.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”